Aterian enters its May 14 earnings report after one of the most violent short-covering episodes the stock has seen in recent memory — and the speed of that unwind raises more questions than it answers.
The defining story of the past two weeks has been the collapse of a significant short position in almost real-time. Short interest hit a peak of 16.2% of free float on April 30. By May 7, it had fallen to just 0.4% — a 96% drop in one week. That is not gradual profit-taking; that is forced covering at scale. The catalyst was a director purchase: David Lazar bought 1.75 million shares on April 27 at $2.00, a $3.5 million commitment that represented the single largest insider transaction in recent company history. Whether that buy triggered the squeeze or simply coincided with it, the timing is impossible to ignore.
The borrow market tells the story of what happened next. Before the Lazar purchase, cost to borrow sat below 4% — unremarkable for a micro-cap. From April 28 it detonated, crossing 77% and then surging above 300% by late April and into early May. It has since eased to roughly 227%, but that is still an extreme level. Availability tightened to near-zero during the peak days, with the lending pool fully depleted from April 29 through May 1. Since then, availability has begun to loosen as shorts exit, but the borrow market remains far from normal. The cost is a direct consequence: lenders are still pricing scarcity even as the short base shrinks.
Options positioning adds a layer of nuance. The put/call ratio is running at 0.27 — noticeably above its 20-day average of 0.20 and about 1.2 standard deviations above the norm. That is mildly elevated rather than alarming, but the directional shift is clear: as the stock gave back nearly 10% on May 8, options traders edged further toward protection. The ORTEX short score has also declined sharply from its recent high of 80.5 on April 30 to 60.2 by May 7 — moving in the same direction as the covering, but still sitting in moderately elevated territory.
The street provides very little active guidance here. Only two analysts cover the stock, split evenly between one Buy and one Hold. The $8.00 mean price target is stale — the most recent analyst change on record dates to May 2024 — and that target is so far above the current $1.10 price level that it provides no useful near-term anchor. Valuation multiples are similarly uninformative for a company generating negative earnings per share. The stock's one genuine bright spot in the data is its EPS surprise rank, which places in the 98th percentile — suggesting the company has a strong record of beating expectations when it does report, a fact worth holding in mind given next Wednesday's print.
On the ownership side, the top two holders — Arturo Rodriguez (CEO, 10.7%) and Joshua Feldman (CFO, 5.2%) — both added to positions in January, while a cluster of insider sells in June 2025 at prices above $1.20 adds some historical context to current levels. The net 90-day insider position is firmly positive, driven entirely by the Lazar buy.
The stock is down 64% from the April 27 close near $2.00 where Lazar bought, now trading at $1.10 after a brutal May 8 session. The 64% one-month rally masks how quickly that gain has given back. Next Wednesday's earnings release is the next focal point: past prints have delivered an average first-day decline of roughly 4%, with deeper five-day drawdowns in one case approaching 18%. With the squeeze largely exhausted, the short base minimal, and cost to borrow still elevated at 227%, the next move for the stock will hinge almost entirely on what the revenue and guidance numbers show.
See the live data behind this article on ORTEX.
Open ATER on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
